中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
12期
34-35
,共2页
膀胱痉挛%托特罗定缓释片%硬膜外镇痛泵
膀胱痙攣%託特囉定緩釋片%硬膜外鎮痛泵
방광경련%탁특라정완석편%경막외진통빙
Cystospasm%Tolterodine tartrate sustained release tablets%Patient controlled epidural analgesic pump
目的：观察托特罗定缓释片联合术后硬膜外镇痛泵在前列腺电切术后膀胱痉挛预防中的疗效。方法将108例接受前列腺电切术的患者随机分为三组，第一组即对照组，术前未预防用药，术后未应用硬膜外自控镇痛泵，当膀胱痉挛出现时予以吲哚美辛栓0.05 g 纳肛缓解症状，术后5~7 d 拔尿管；第二组术前2 h 服用托特罗定缓释片4 mg，术后继续口服托特罗定缓释片4 mg，1次/ d，术后5~7 d 拔尿管，拔管前1 d 停药，术后未应用硬膜外自控镇痛泵，当膀胱痉挛出现时予以吲哚美辛栓0.05 g 纳肛缓解症状；第三组术前2 h 服用托特罗定缓释片4 mg，术后继续口服托特罗定缓释片4 mg，1次/ d，术后5~7 d 拔尿管，拔管前1 d 停药，术后应用硬膜自控镇痛泵，当膀胱痉挛出现时予以吲哚美辛栓0.05 g 纳肛缓解症状。结果托特罗定缓释片﹢术后硬膜外镇痛泵组术后72 h 内膀胱痉挛次数、膀胱痉挛持续时间均少于托特罗定组和对照组。结论托特罗定缓释片联合术后硬膜外镇痛泵在前列腺电切术后膀胱痉挛预防中的疗效显著。
目的：觀察託特囉定緩釋片聯閤術後硬膜外鎮痛泵在前列腺電切術後膀胱痙攣預防中的療效。方法將108例接受前列腺電切術的患者隨機分為三組，第一組即對照組，術前未預防用藥，術後未應用硬膜外自控鎮痛泵，噹膀胱痙攣齣現時予以吲哚美辛栓0.05 g 納肛緩解癥狀，術後5~7 d 拔尿管；第二組術前2 h 服用託特囉定緩釋片4 mg，術後繼續口服託特囉定緩釋片4 mg，1次/ d，術後5~7 d 拔尿管，拔管前1 d 停藥，術後未應用硬膜外自控鎮痛泵，噹膀胱痙攣齣現時予以吲哚美辛栓0.05 g 納肛緩解癥狀；第三組術前2 h 服用託特囉定緩釋片4 mg，術後繼續口服託特囉定緩釋片4 mg，1次/ d，術後5~7 d 拔尿管，拔管前1 d 停藥，術後應用硬膜自控鎮痛泵，噹膀胱痙攣齣現時予以吲哚美辛栓0.05 g 納肛緩解癥狀。結果託特囉定緩釋片﹢術後硬膜外鎮痛泵組術後72 h 內膀胱痙攣次數、膀胱痙攣持續時間均少于託特囉定組和對照組。結論託特囉定緩釋片聯閤術後硬膜外鎮痛泵在前列腺電切術後膀胱痙攣預防中的療效顯著。
목적：관찰탁특라정완석편연합술후경막외진통빙재전렬선전절술후방광경련예방중적료효。방법장108례접수전렬선전절술적환자수궤분위삼조，제일조즉대조조，술전미예방용약，술후미응용경막외자공진통빙，당방광경련출현시여이신타미신전0.05 g 납항완해증상，술후5~7 d 발뇨관；제이조술전2 h 복용탁특라정완석편4 mg，술후계속구복탁특라정완석편4 mg，1차/ d，술후5~7 d 발뇨관，발관전1 d 정약，술후미응용경막외자공진통빙，당방광경련출현시여이신타미신전0.05 g 납항완해증상；제삼조술전2 h 복용탁특라정완석편4 mg，술후계속구복탁특라정완석편4 mg，1차/ d，술후5~7 d 발뇨관，발관전1 d 정약，술후응용경막자공진통빙，당방광경련출현시여이신타미신전0.05 g 납항완해증상。결과탁특라정완석편﹢술후경막외진통빙조술후72 h 내방광경련차수、방광경련지속시간균소우탁특라정조화대조조。결론탁특라정완석편연합술후경막외진통빙재전렬선전절술후방광경련예방중적료효현저。
Objective To observe the curative effects of tolterodine tartrate sustained release tablets combine with patient controlled epidural analgesic pump(PCEA)on prevented cystospasm after transurethral resection of the prostate(TURP). Methods One hundred and eight patients with cysto-spasm after TURP were divided into 3 groups randomly. The patients in the first group(control group) were not given preoperative medication,or PECA after operation,but accepted rectum administration of indometacin suppositories 0. 05 g when cystospasm occured. And the catheter was pulled out at 5 - 7 days after surgery. The patients in the second group were given tolterodine tartrate sustained release tablet 4 mg at 2 hours before surgery,and were given 4 mg per day after surgery. The catheter was pulled out at 5 - 7 days after surgery,and the medication was discontinued on 1 day before extubation,but didn’t ac-cept PCEA after surgery,and accept rectum administration of indometacin suppositories 0. 05 g when cys-tospasm occured. The patients in the third group were given tolterodine tartrate sustained release tablet 4 mg at 2 hours before surgery,and were given 4 mg per day after surgery. The catheter was pulled out at 5 - 7 days after surgery,and medication was discontinued on 1 day before extubation,and accepted PCEA after surgery,were given rectum administration of indometacin suppositories 0. 05 g when cysto-spasm occued. Results The frequency and duration of cystospasm in the third group within 72 hours af-ter surgery were less than those in the other groups. Conclusions The effect of tolterodine tartrate sus-tained release tablets combine with PCEA on prevented cystospasm after TURP is significant.
